ProQR Therapeutics News

ProQR Therapeutics Analyst Ratings

BenzingaApr 18 11:57 ET

ProQR Therapeutics Analyst Ratings

BenzingaMar 14 06:26 ET

Chardan Capital Upgrades ProQR Therapeutics to Buy, Announces $2 Price Target

BenzingaNov 8, 2023 05:19 ET

ProQR Therapeutics Analyst Ratings

BenzingaNov 8, 2023 05:17 ET

Buy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Position

TipRanksNov 7, 2023 14:35 ET

Citigroup Maintains Buy on ProQR Therapeutics, Lowers Price Target to $1.8

BenzingaSep 18, 2023 09:41 ET

ProQR Therapeutics Analyst Ratings

BenzingaSep 18, 2023 09:39 ET

ProQR Therapeutics Analyst Ratings

BenzingaAug 7, 2023 06:14 ET

ProQR Therapeutics Analyst Ratings

BenzingaAug 4, 2023 04:59 ET

Chardan Assigns New Price Target of $2 to ProQR Therapeutics, Keeps Neutral Rating

MT NewswiresMay 24, 2023 06:32 ET

Cantor Fitzgerald Adjusts Price Target on ProQR Therapeutics to $4.50 From $5, Maintains Overweight Rating

MT NewswiresMay 17, 2023 10:10 ET

Cantor Fitzgerald Maintains Overweight on ProQR Therapeutics, Lowers Price Target to $4.5

BenzingaMay 17, 2023 09:51 ET

HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

BenzingaMay 17, 2023 06:26 ET

HC Wainwright Raises Price Target on ProQR Therapeutics to $5 From $1.50, Maintains Buy Rating

MT NewswiresMar 30, 2023 09:35 ET

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $6 Price Target

BenzingaMar 30, 2023 09:16 ET

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $5

BenzingaMar 30, 2023 06:28 ET

Tesla To $175? Here Are 10 Other Price Target Changes For Friday

Benzinga Real-time NewsDec 23, 2022 09:22 ET

Raymond James Adjusts ProQR Therapeutics Price Target to $5 From $2, Maintains Outperform Rating

MT NewswiresDec 23, 2022 07:42 ET

Cantor Fitzgerald Upgrades ProQR Therapeutics to Overweight From Neutral, Adjusts Price Target to $5 From $0.80

MT NewswiresDec 22, 2022 11:17 ET

ProQR Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesAug 15, 2022 09:16 ET